

## Minutes: Steering Board meeting, 31 December 2020

### 1. Update on the Allocation of doses and implementation of contracts

An exceptional Steering Board meeting was organized to accommodate further changes in the allocation table for the optional doses of the Pfizer/BioNtech vaccine.

More concretely, [REDACTED] Member States [REDACTED] requested their pro-rata allocation from the [REDACTED] optional doses after having originally declined any optional volume.

On this occasion, the Commission informed that, following a meeting with representatives of Pfizer/BioNtech during the week:

- [REDACTED]
- given the high demand from the MSs and the mandate from the Steering Board to start the exploratory discussions **for a top-up of [REDACTED] additional doses**, the Commission outlined this interest to the company that **confirmed its capacity to deliver [REDACTED] in the 2021 [REDACTED]**

In this light, [REDACTED] raised two questions *in a tour de table*, namely:

#### 1. On the MSs' interest **in a top up of [REDACTED] doses**.

The **overwhelming majority of MSs showed interest in the top-up** (no Member State was against), for some pending political agreement [REDACTED]. Some even expressed the wish for more than the proposed top-up volume.

On this basis the Commission **was mandated** to go back to the company and **confirm the strong interest** of the Member States in the top-up for doses of BioNtech-Pfizer Vaccine and sound possibilities for quantities above [REDACTED] doses.

#### 2. On the MSs's willingness (especially those having more than the pro-rata) to share optional doses with [REDACTED]

The Member States having opted for more than the pro-rata expressed their willingness to share optional doses with the [REDACTED] MSs, others either indicated that would like to stick to their pro rata, or expressed interest to share, pending political approval.

[REDACTED]

This discussion will be concluded at the next Steering Board when the all the MSs would be able to take a formal position.

